Olmesartan Medoxomil Actavis

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomil Actavis, is an Angiotensin II receptor blocker (ARB) presented as a tablet for oral use. It is indicated for the management of hypertension in adult patients. GNH USA supplies Olmesartan Medoxomil Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmesartan Medoxil Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan medoxil is an ARB that lowers blood pressure by blocking the renin‑angiotensin system.

- Hypertension: helps achieve target blood pressure and reduces cardiovascular risk. - Diabetic nephropathy: slows progression of kidney damage associated with type 2 diabetes. - Heart failure: used as part of combination therapy to improve symptoms and outcomes.

Adverse reactions to olmesartan medoxil are generally mild to moderate and vary with individual tolerance.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Nasal congestion - Diarrhoea - Cough

Serious or Rare Side Effects: - Angio‑edema involving the face, lips or tongue - Severe hypotension - Acute kidney injury - Hyperkalemia - Liver enzyme elevations - Allergic skin reactions such as Stevens‑Johnson syndrome

When prescribing olmesartan medoxil, clinicians should consider several safety aspects.

- Blood pressure monitoring: ensure adequate control without excessive lowering. - Renal function: assess baseline creatinine and eGFR, adjust if impaired. - Electrolytes: monitor potassium levels, especially with concomitant potassium‑sparing agents. - Pregnancy: contraindicated in the second and third trimesters due to fetal toxicity. - Drug interactions: review concomitant antihypertensives and NSAIDs for additive effects. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan medoxil may interact with several medicines that affect blood pressure, renal function, or potassium balance.

Major Interactions (Avoid): - Aliskiren: combined use in diabetic patients increases risk of renal impairment and hyperkalaemia. - Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous hyperkalaemia. - ACE inhibitors: concurrent use can lead to additive hypotensive effects and renal dysfunction.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive response and affect renal function. - Lithium: ARBs can increase lithium levels, risking toxicity. - Diuretics (thiazides): may enhance hypotensive effect and alter electrolytes.